Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Seaweed, particularly certain brown and red varieties, has been studied for its potential role in blood clot prevention due to its rich content of bioactive compounds such as sulfated polysaccharides (e.g., fucoidan, carrageenan, and alginate). Scientific research, primarily in vitro and in animal models, has demonstrated that these compounds can exhibit anticoagulant and antithrombotic activities, sometimes resembling or even surpassing those of heparin, a widely used anticoagulant drug.

The mechanisms proposed involve the inhibition of key enzymes in the coagulation cascade, such as thrombin and factor Xa, as well as the modulation of platelet aggregation. Some human studies exist, but they are limited in scale and mostly preliminary. For example, small clinical trials and observational studies suggest that regular consumption of edible seaweed may be associated with improved cardiovascular health and reduced blood viscosity, which could theoretically contribute to a lower risk of clot formation.

Despite these promising findings, there is insufficient large-scale, randomized clinical trial data to firmly establish seaweed as a reliable therapy for blood clot prevention. Additionally, the anticoagulant potency of seaweed extracts can vary greatly depending on species, preparation, and dosage. Therefore, while there is scientific promise and a moderate evidence base (hence a rating of 3), more robust clinical research is necessary before seaweed can be recommended as a mainstream intervention for blood clot prevention.

More about seaweed
More about Blood Clots (prevention of)

Other ingredients used for Blood Clots (prevention of)

Other health conditions supported by seaweed

Products containing seaweed